Variable | CCRT group (n = 49) | IC plus RT group (n = 49) | IC plus CCRT group (n = 49) | P value* |
---|---|---|---|---|
Total Grade 3–4 acute adverse events | 16 (32.7 %) | 19 (38.8 %) | 20 (40.8 %) | 0.685 |
Hematologic | ||||
 Leukopenia | 4 (8.2 %) | 10 (20.4 %) | 11 (22.4 %) | 0.126 |
 Neutropenia | 3 (6.1 %) | 9 (18.4 %) | 9 (18.4 %) | 0.135 |
 Anemia | 0 (0 %) | 1 (2 %) | 1 (2 %) | 1.000 |
 Thrombocytopenia | 2 (4.1 %) | 2 (4.1 %) | 2 (4.1 %) | 1.000 |
Non–hematologic | ||||
 Dermatitis | 1 (2 %) | 2 (4.1 %) | 2 (4.1 %) | 1.000 |
 Mucositis | 11 (22.4 %) | 7 (14.3 %) | 12 (24.5 %) | 0.415 |
 Dysphagia | 1 (2 %) | 0 (0 %) | 1 (2 %) | 1.000 |
 Nausea/vomiting | 2 (4.1 %) | 2 (4.1 %) | 3 (6.1 %) | 1.000 |
 Dry mouth | 0 (0 %) | 0 (0 %) | 0 (0 %) | - |
 Ototoxicity | 0 (0 %) | 0 (0 %) | 0 (0 %) | - |
 Hepatoxicity | 0 (0 %) | 3 (6.1 %) | 1 (2 %) | 0.324 |
 Nephrotoxicity | 0 (0 %) | 0 (0 %) | 0 (0 %) | - |
 Neurotoxicity | 0 (0 %) | 0 (0 %) | 0 (0 %) | - |